Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
81 hedge funds and large institutions have $23.6M invested in Kezar Life Sciences in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 17 increasing their positions, 26 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.9% less ownership
Funds ownership: 6.31% → 5.41% (-0.9%)
5% less funds holding
Funds holding: 85 → 81 (-4)
12% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 26
35% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 26
42% less capital invested
Capital invested by funds: $40.4M → $23.6M (-$16.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$798K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$646K |
| 3 |
Goldman Sachs
New York
|
+$467K |
| 4 |
Jane Street
New York
|
+$399K |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
+$225K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.88M |
| 2 |
State Street
Boston,
Massachusetts
|
-$713K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$690K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$630K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$621K |
KZR Hedge Fund Activity: Q2 2024 in Review
81 of the 6,929 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2024, worth a combined $23.6M — down 42% from $40.4M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of KZR and 23 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 17 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $798K. The largest seller was BlackRock, cutting an estimated $2.88M.
- 81 institutional investors held Kezar Life Sciences (KZR) as of Q2 2024, down from 85 in Q1 2024.
- Funds reported $23.6M of Kezar Life Sciences stock for Q2 2024, down 42% quarter-over-quarter.
- 23 funds opened new Kezar Life Sciences positions in Q2 2024 and 26 closed out, a net change of -3 holders.
- The largest Kezar Life Sciences buyer in Q2 2024 was Stonepine Capital Management, an estimated $798K added.
- The largest Kezar Life Sciences seller in Q2 2024 was BlackRock, an estimated $2.88M sold.
Based on aggregated 13F filings for Q2 2024.